$8.78
3.41% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US71722W1071
Symbol
PHAT
Sector
Industry

Phathom Pharmaceuticals Inc Target price 2024 - Analyst rating & recommendation

Phathom Pharmaceuticals Inc Classifications & Recommendation:

Buy
86%
Hold
14%

Phathom Pharmaceuticals Inc Price Target

Target Price $25.29
Price $8.78
Potential
Number of Estimates 7
7 Analysts have issued a price target Phathom Pharmaceuticals Inc 2025 . The average Phathom Pharmaceuticals Inc target price is $25.29. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 7 analysts: 6 Analysts recommend Phathom Pharmaceuticals Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Phathom Pharmaceuticals Inc stock has an average upside potential 2025 of . Most analysts recommend the Phathom Pharmaceuticals Inc stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 0.68 50.24
7,287.99%
EBITDA Margin -24,520.59% -497.33%
97.97%
Net Margin -39,484.94% -755.44%
98.09%

7 Analysts have issued a sales forecast Phathom Pharmaceuticals Inc 2024 . The average Phathom Pharmaceuticals Inc sales estimate is

$50.2m
Unlock
. This is
91.24% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$55.6m 111.65%
Unlock
, the lowest is
$43.5m 65.68%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $680k
2024
$50.2m 7,287.99%
Unlock
2025
$172m 242.10%
Unlock
2026
$379m 120.26%
Unlock
2027
$595m 57.28%
Unlock
2028
$757m 27.15%
Unlock

4 Analysts have issued an Phathom Pharmaceuticals Inc EBITDA forecast 2024. The average Phathom Pharmaceuticals Inc EBITDA estimate is

$-250m
Unlock
. This is
12.99% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-213m 25.92%
Unlock
, the lowest is
$-285m 0.77%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-167m 2.96%
2024
$-250m 49.85%
Unlock
2025
$-196m 21.56%
Unlock
2026
$-39.8m 79.70%
Unlock
2027
$87.5m 319.87%
Unlock
2028
$147m 68.18%
Unlock

EBITDA Margin

2023 -24,520.59%
2024
-497.33% 97.97%
Unlock
2025
-114.03% 77.07%
Unlock
2026
-10.51% 90.78%
Unlock
2027
14.70% 239.87%
Unlock
2028
19.44% 32.24%
Unlock

2 Phathom Pharmaceuticals Inc Analysts have issued a net profit forecast 2024. The average Phathom Pharmaceuticals Inc net profit estimate is

$-380m
Unlock
. This is
2.37% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-376m 3.16%
Unlock
, the lowest is
$-383m 1.58%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-268m 22.18%
2024
$-380m 41.35%
Unlock
2025
$-260m 31.50%
Unlock
2026
$-22.6m 91.33%
Unlock
2027
$153m 778.67%
Unlock
2028
$169m 10.71%
Unlock

Net Margin

2023 -39,484.94%
2024
-755.44% 98.09%
Unlock
2025
-151.26% 79.98%
Unlock
2026
-5.96% 96.06%
Unlock
2027
25.70% 531.21%
Unlock
2028
22.38% 12.92%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -3.93 -5.56
22.18% 41.48%
P/E negative
EV/Sales 15.62

2 Analysts have issued a Phathom Pharmaceuticals Inc forecast for earnings per share. The average Phathom Pharmaceuticals Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-5.56
Unlock
. This is
2.28% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-5.51 3.16%
Unlock
, the lowest is
$-5.60 1.58%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-3.93 22.18%
2024
$-5.56 41.48%
Unlock
2025
$-3.81 31.47%
Unlock
2026
$-0.33 91.34%
Unlock
2027
$2.24 778.79%
Unlock
2028
$2.48 10.71%
Unlock

P/E ratio

Current -1.54 21.43%
2024
-1.58 2.60%
Unlock
2025
-2.31 46.20%
Unlock
2026
-26.61 1,051.95%
Unlock
2027
3.92 114.73%
Unlock
2028
3.54 9.69%
Unlock

Based on analysts' sales estimates for 2024, the Phathom Pharmaceuticals Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

15.62
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
11.95
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 29.87
2024
15.62 47.71%
Unlock
2025
4.57 70.77%
Unlock
2026
2.07 54.60%
Unlock
2027
1.32 36.42%
Unlock
2028
1.04 21.35%
Unlock

P/S ratio

Current
2024
11.95 47.71%
Unlock
2025
3.49 70.77%
Unlock
2026
1.59 54.60%
Unlock
2027
1.01 36.41%
Unlock
2028
0.79 21.36%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today